The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID)

Basit Öğe Kaydı
dc.authorid0000-0003-3307-0948
dc.authorid0000-0003-3463-7555
dc.authorid0000-0002-0731-5799
dc.contributor.authorBayrakçı, Benan
dc.contributor.authorErsoy, Fügen
dc.contributor.authorSanal, Özden
dc.contributor.authorKılıç, Şebnem
dc.contributor.authorMetin, Ayşe
dc.date.accessioned2021-06-23T18:54:26Z
dc.date.available2021-06-23T18:54:26Z
dc.date.issued2005
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractImmunoglobulin replacement therapy is the essential treatment of B-cell deficiencies. Because of the high expense of therapy, optimal dose, infusion intervals and serum IgG levels should be well defined. Data of 19 X-linked agammaglobulinemia (XLA), 7 hyper-IgM syndrome (HIM) and 20 common variable immunodeficiency (CVID) patients were analyzed. Infection frequencies and hospitalization requirements were correlated with the immunoglobulin doses used and serum IgG levels achieved. The characteristics before diagnosis and after treatment were compared among the XLA, HIM and CVID groups. By using a median dose of 370 mg/kg/month immunoglobulin, which maintained serum IgG levels at a median concentration of 440 mg/dl, the annual incidence of infections dropped from 12.4 to 3.2 and annual hospitalization requirements decreased from 1.6 to 0.16 per patient. Serum IgG levels of 300-500 mg/dl were found to be satisfactory, except in the CVID group. Increasing the level over 500 mg/dl neither prevented pneumonia further nor decreased the need for hospitalization. Monthly replacement was found to be adequate, except for XLA patients. Serum IgG levels between 300-500 mg/dl are sufficient for effective treatment of hypogammaglobulinemias. These concentrations can be maintained with 300-400 mg/kg/month doses. Higher doses and IgG levels are not needed.en_US
dc.identifier.endpage246en_US
dc.identifier.issn0041-4301
dc.identifier.issue3en_US
dc.identifier.pmid16250308en_US
dc.identifier.scopus2-s2.0-27544442575en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage239en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/4433
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-27544442575&partnerID=40&md5=2304999341d78df9e781b61f727157c0
dc.identifier.volume47en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıç, Şebnem
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Pediatricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdverse reactionen_US
dc.subjectComplicationen_US
dc.subjectHospitalizationen_US
dc.subjectImmunoglobulinen_US
dc.subjectInfectionen_US
dc.titleThe efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID)en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
benan-bayrakcı.pdf
Boyut:
305.31 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/ Full text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu